Verified July 2026 · Cited to primary sources
LL-37 (Cathelicidin): Evidence Grade C. Early / foreign human data only.
The honest verdict
An interesting molecule with an honest evidence problem. Because it is the body's own antimicrobial peptide with plausible wound-healing biology, it draws attention, and there is a positive small human trial. But the larger, more rigorous trial did not confirm it, which is exactly the pattern you should respect rather than explain away. Grade C, and specifically the kind of C where the definitive data leaned negative. Not something to self-inject, and the wound-healing story is unproven, not promising-and-confirmed.
LL-37 (Cathelicidin) at a glance
- Class
- Host-defense (antimicrobial) peptide
- Mechanism
- LL-37 is the only human cathelicidin, released from a precursor protein (hCAP-18) by immune and skin cells. It punches holes in bacterial membranes to kill microbes directly, but it does more than that: it neutralizes bacterial toxins, recruits immune cells, promotes new blood vessel growth, and drives the migration of skin cells that close wounds. Those wound-healing and immune-signaling roles, not just the antibacterial action, are why it gets studied as a topical for hard-to-heal ulcers.
- Also known as
- LL37, Cathelicidin, hCAP-18, CAP-18, Cathelicidin antimicrobial peptide
- Research applications
- Hard-to-heal venous leg ulcers (topical)
- Chronic and infected wound healing
- Antimicrobial and anti-biofilm applications
- Immune modulation research
- Skin barrier and inflammatory skin conditions
- Forms
- Topical gel or solution (wound-healing trials), Subcutaneous injection (research use)
- Legal status
- Research-only
- WADA (anti-doping)
- Not on the WADA Prohibited List and not a recognized performance-enhancing agent. It is a host-defense peptide, not an anabolic or growth agent.
- Evidence grade
- Grade CEarly / foreign human data only
How we grade evidence
Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is LL-37 (Cathelicidin)?
The body's own 37-amino-acid antimicrobial peptide. It has genuine human wound-healing trials, but the largest one (phase 2b) failed its main endpoint, so the evidence is a mixed, small-scale C.
LL-37 is the only human cathelicidin, released from a precursor protein (hCAP-18) by immune and skin cells. It punches holes in bacterial membranes to kill microbes directly, but it does more than that: it neutralizes bacterial toxins, recruits immune cells, promotes new blood vessel growth, and drives the migration of skin cells that close wounds. Those wound-healing and immune-signaling roles, not just the antibacterial action, are why it gets studied as a topical for hard-to-heal ulcers.
How strong is the evidence for LL-37 (Cathelicidin)?
There is real human trial data, which keeps it above animal-only, but the results are genuinely mixed. A small first-in-man phase 1/2a study (n=34) in venous leg ulcers found lower doses of topical LL-37 healed several-fold faster than placebo. But the larger, better-powered phase 2b multicentric RCT (n=148) was NEGATIVE for the overall population, with only a post-hoc signal in patients with large ulcers. So the honest read is: a positive small trial, a failed larger trial, and a subgroup hint that needs confirming. That is a small-human-pilot picture with a caution flag, not proof of efficacy.
Primary sources (2)
Is LL-37 (Cathelicidin) legal? (Status July 2026)
No legal supervised US route.
What is LL-37 (Cathelicidin) used for?
LL-37 (Cathelicidin) is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.
What does LL-37 (Cathelicidin) cost, and how do you access it legally?
Typical cost
$40 to $100 per vial (research-grade, typically 5mg)
Sold as a research-grade peptide with unverified purity. There is no FDA-approved LL-37 product, so any consumer material is unregulated and its identity and sterility are not guaranteed.
No legal supervised access route right now.
LL-37 (Cathelicidin) has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole, so we don't link them. If you pursue LL-37 (Cathelicidin), do it with a licensed clinician, and re-check its legal status first.
Is LL-37 (Cathelicidin)safe? Side effects & risks
In the topical wound trials, LL-37 was well tolerated locally with no major systemic safety signals, which is the main reassurance. But that is topical, low-dose, short-term data on damaged skin. Human safety for injected or systemic LL-37 is essentially unstudied, and at high concentrations LL-37 can be toxic to host cells and has been linked in the literature to some inflammatory and autoimmune skin conditions (for example rosacea and psoriasis biology). Research-only with no manufacturing oversight. Do not inject.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
LL-37 (Cathelicidin) FAQ
What is LL-37?
It is the only cathelicidin antimicrobial peptide humans make. Your immune and skin cells release it to kill microbes and help coordinate wound healing. The synthetic version is studied mostly as a topical for chronic wounds.
Does it heal wounds in humans?
The evidence is mixed. A small early trial in venous leg ulcers looked positive at low doses, but a larger, better-designed phase 2b trial failed its main endpoint and only showed a hint of benefit in a subgroup with large ulcers. So it is unproven, not established.
Is it safe to use?
Topically in trials it was well tolerated, but there is no real human safety data for injecting it, and at high concentrations LL-37 can damage host cells and is tied to some inflammatory skin conditions. It is research-only with no quality oversight.
From our portfolio
Tracking LL-37 (Cathelicidin)?
Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.
Keep reading
KPV
An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans.
Grade BThymosin Alpha-1
A 28-amino-acid thymic peptide that tunes the immune system. Approved as a drug (Zadaxin) in ~35 countries for hepatitis and immune support, but never FDA-approved, so in the US it is research-only.
Grade CVIP (Vasoactive Intestinal Peptide / Aviptadil)
A natural 28-amino-acid neuropeptide with broad signaling roles. Its big FDA push (aviptadil for COVID) failed a phase 3 trial and the FDA declined authorization, so the evidence is a mixed C.
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.